Unveiling 17 Analyst Insights On Merck & Co

Loading...
Loading...

Providing a diverse range of perspectives from bullish to bearish, 17 analysts have published ratings on Merck & Co MRK in the last three months.

The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.

Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish
Total Ratings 4 10 2 0 1
Last 30D 0 1 0 0 0
1M Ago 2 3 1 0 0
2M Ago 0 2 0 0 1
3M Ago 2 4 1 0 0

In the assessment of 12-month price targets, analysts unveil insights for Merck & Co, presenting an average target of $135.35, a high estimate of $148.00, and a low estimate of $104.00. This upward trend is apparent, with the current average reflecting a 2.54% increase from the previous average price target of $132.00.

Decoding Analyst Ratings: A Detailed Look

In examining recent analyst actions, we gain insights into how financial experts perceive Merck & Co. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target
Louise Chen Cantor Fitzgerald Maintains Overweight $135.00 -
Luisa Hector Berenberg Raises Buy $143.00 $140.00
Louise Chen Cantor Fitzgerald Maintains Overweight $135.00 -
Louise Chen Cantor Fitzgerald Maintains Overweight $135.00 -
Robyn Karnauskas Truist Securities Raises Buy $142.00 $139.00
Louise Chen Cantor Fitzgerald Maintains Overweight $135.00 -
Mohit Bansal Wells Fargo Raises Equal-Weight $135.00 $130.00
Justin Smith Societe Generale Announces Sell $104.00 -
Louise Chen Cantor Fitzgerald Maintains Overweight $135.00 -
Louise Chen Cantor Fitzgerald Maintains Overweight $135.00 -
Louise Chen Cantor Fitzgerald Maintains Overweight $135.00 -
Louise Chen Cantor Fitzgerald Maintains Overweight $135.00 -
Robyn Karnauskas Truist Securities Raises Buy $139.00 $122.00
Colin Bristow UBS Raises Buy $148.00 $135.00
Mohit Bansal Wells Fargo Raises Equal-Weight $130.00 $125.00
Carter Gould Barclays Raises Overweight $145.00 $135.00
Carter Gould Barclays Raises Overweight $135.00 $130.00

Key Insights:

Loading...
Loading...
  • Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Merck & Co. This information provides a snapshot of how analysts perceive the current state of the company.
  • Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Merck & Co compared to the broader market.
  • Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Merck & Co's stock. This comparison reveals trends in analysts' expectations over time.

To gain a panoramic view of Merck & Co's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.

Stay up to date on Merck & Co analyst ratings.

Discovering Merck & Co: A Closer Look

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.

Merck & Co: A Financial Overview

Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.

Revenue Growth: Merck & Co's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2023, the company achieved a revenue growth rate of approximately 5.78%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.

Net Margin: Merck & Co's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -8.38%, the company may face hurdles in effective cost management.

Return on Equity (ROE): Merck & Co's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -3.11%, the company may face hurdles in achieving optimal financial performance.

Return on Assets (ROA): Merck & Co's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -1.15%, the company may face hurdles in generating optimal returns from its assets.

Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 0.93, caution is advised due to increased financial risk.

Analyst Ratings: What Are They?

Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.

Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Loading...
Loading...
Market News and Data brought to you by Benzinga APIs
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst RatingsBZI-AAR
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...